Allergy Therapeutics plc (AGY.L)
- Previous Close
2.8000 - Open
0.0000 - Bid 2.8000 x --
- Ask --
- Day's Range
0.0000 - 0.0000 - 52 Week Range
0.0000 - 6.2500 - Volume
600,000 - Avg. Volume
716,348 - Market Cap (intraday)
135.844M - Beta (5Y Monthly) 1.34
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0600 - Earnings Date Mar 27, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Allergy Therapeutics plc, a commercial biotechnology company, engages in the research and development of allergy treatments. The company sells injectable and sublingual allergen-specific immunotherapies; and offers prescription for the treatment of pollen-related allergies particularly to grasses, weeds, and trees, as well as diagnostics. Its products include Pollinex Quattro, Oralvac, Venomil, Venom ATL Polistes Dominula, Acarovac Plus, Pollinex, Synbiotics, and VLP Peanut. The company develops allergy vaccines for pollen, house dust mites, and animal fur, as well as peanut allergy vaccines. It operates in Central Europe, Southern Europe, the United Kingdom, and internationally. Allergy Therapeutics plc was incorporated in 2004 and is headquartered in Worthing, the United Kingdom.
www.allergytherapeutics.com612
Full Time Employees
June 30
Fiscal Year Ends
Sector
Recent News: AGY.L
Performance Overview: AGY.L
Trailing total returns as of 4/24/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: AGY.L
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: AGY.L
Valuation Measures
Market Cap
133.46M
Enterprise Value
129.79M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.89
Price/Book (mrq)
5.04
Enterprise Value/Revenue
2.44
Enterprise Value/EBITDA
-3.33
Financial Highlights
Profitability and Income Statement
Profit Margin
-94.29%
Return on Assets (ttm)
-34.76%
Return on Equity (ttm)
-155.90%
Revenue (ttm)
53.26M
Net Income Avi to Common (ttm)
-50.22M
Diluted EPS (ttm)
-0.0600
Balance Sheet and Cash Flow
Total Cash (mrq)
13.52M
Total Debt/Equity (mrq)
37.22%
Levered Free Cash Flow (ttm)
-17.3M
Research Analysis: AGY.L
Company Insights: AGY.L
AGY.L does not have Company Insights